205 related articles for article (PubMed ID: 15298581)
1. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
Donnelly M; Haby MM; Carter R; Andrews G; Vos T
Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
3. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
4. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
5. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
Efron D; Jarman F; Barker M
Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
[TBL] [Abstract][Full Text] [Related]
6. Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Erder MH; Signorovitch JE; Setyawan J; Yang H; Parikh K; Betts KA; Xie J; Hodgkins P; Wu EQ
J Med Econ; 2012; 15(6):1078-87. PubMed ID: 22537226
[TBL] [Abstract][Full Text] [Related]
7. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
Efron D; Jarman F; Barker M
Pediatrics; 1997 Oct; 100(4):662-6. PubMed ID: 9310521
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Marchetti A; Magar R; Lau H; Murphy EL; Jensen PS; Conners CK; Findling R; Wineburg E; Carotenuto I; Einarson TR; Iskedjian M
Clin Ther; 2001 Nov; 23(11):1904-21. PubMed ID: 11768842
[TBL] [Abstract][Full Text] [Related]
9. Treatment of attention-deficit/hyperactivity disorder.
Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil.
Maia CR; Stella SF; Wagner F; Pianca TG; Krieger FV; Cruz LN; Polanczyk GV; Rohde LA; Polanczyk CA
Braz J Psychiatry; 2016 Mar; 38(1):30-8. PubMed ID: 26375808
[TBL] [Abstract][Full Text] [Related]
11. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
Schawo S; van der Kolk A; Bouwmans C; Annemans L; Postma M; Buitelaar J; van Agthoven M; Hakkaart-van Roijen L
Pharmacoeconomics; 2015 May; 33(5):489-509. PubMed ID: 25715975
[TBL] [Abstract][Full Text] [Related]
12. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
[TBL] [Abstract][Full Text] [Related]
13. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
14. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.
Preen DB; Calver J; Sanfilippo FM; Bulsara M; Holman CD
Aust N Z J Public Health; 2007 Apr; 31(2):120-6. PubMed ID: 17461001
[TBL] [Abstract][Full Text] [Related]
15. Update on drugs for hyperactivity in childhood.
Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
[TBL] [Abstract][Full Text] [Related]
16. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
[TBL] [Abstract][Full Text] [Related]
17. Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.
Efron D; Jarman FC; Barker MJ
J Paediatr Child Health; 1998 Jun; 34(3):288-92. PubMed ID: 9633980
[TBL] [Abstract][Full Text] [Related]
18. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.
Castellanos FX; Giedd JN; Elia J; Marsh WL; Ritchie GF; Hamburger SD; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):589-96. PubMed ID: 9136492
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD.
Jensen PS; Garcia JA; Glied S; Crowe M; Foster M; Schlander M; Hinshaw S; Vitiello B; Arnold LE; Elliott G; Hechtman L; Newcorn JH; Pelham WE; Swanson J; Wells K
Am J Psychiatry; 2005 Sep; 162(9):1628-36. PubMed ID: 16135621
[TBL] [Abstract][Full Text] [Related]
20. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
Štuhec M; Locatelli I; Švab V
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
